

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 11748-006-999	APPLICATION NO. 10/516,759
	APPLICANT Mingdong Zhou	
	FILING DATE March 3, 2006	ART UNIT 1642

U.S. PATENT DOCUMENTS						
*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	A01	2004/0197332	10/07/04	Ullrich et al.		
	A02	2005/0136494	06/23/05	Akita et al.		
	A03	5,183,884	02/02/93	Kraus et al.		
	A04	5,480,968	01/02/96	Kraus et al.		
	A05	5,578,482	11/26/96	Lippman et al.		
	A06	5,686,102	11/11/97	Gross et al.		
	A07	5,736,154	04/07/98	Fuisz		
	A08	5,741,511	04/21/98	Lee et al.		
	A09	5,820,859	10/13/98	Kraus et al.		
	A10	5,886,039	03/23/99	Kock et al.		
	A11	5,941,868	08/24/99	Kaplan et al.		
	A12	5,968,511	10/19/99	Akita et al.		
	A13	6,197,801	03/06/01	Lin		
	A14	6,258,374	07/10/01	Friess et al.		
	A15	7,285,649	10/23/07	Akita et al.		
FOREIGN PATENT DOCUMENTS						
*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	EP 0 502 927	10/02/97	Genentech Inc.		
	B02	EP 0 896 586	06/13/91	U.S. Dept of Commerce		
	B03	WO 91/02062	02/21/91	Triton Biosciences		
	B04	WO 91/08214	06/13/91	U.S. Dept of Commerce		
	B05	WO 97/35885	10/02/97	Genentech Inc.		
	B06	WO 98/02540	01/22/98	Genentech Inc.		
	B07	WO 98/30704	07/16/98	Beth Israel Deaconess Medical Center		
	B08	WO 98/35036	08/13/98	Genentech, Inc.		
	B09	WO 01/87334	11/22/01	Pharmacia Italia S.P.A.		
	B10	WO 03/013602	02/20/03	Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V.		
	B11	WO 2006/091209	08/31/06	Merrimack Pharmaceuticals, Inc.		
	B12	WO 2008/100624	08/21/08	Merrimack Pharmaceuticals, Inc.		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11748-006-999	10/516,759
	APPLICANT	
	Mingdong Zhou	
	FILING DATE	ART UNIT
	March 3, 2006	1642

U.S. PATENT DOCUMENTS				
*Examiner Initials	Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
NON PATENT LITERATURE DOCUMENTS				
*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T
	C01	ALIMANDI et al., 1995, "Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas." Oncogene 10:1813-1821		
	C02	AUERBACH & AUERBACH, 1994, "Angiogenesis inhibition: A review." Pharmacol. Ther. 63(3):265-311		
	C03	BEI et al., 1999, "Immune Responses to all ErbB family receptors detectable in serum of cancer patients." Oncogene 18(6):1267-1275		
	C04	CHAN et al., 1995, "Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3." J. Biol. Chem. 270:22608-22613		
	C05	CHEN et al., 1996, "An Immunological Approach Reveals Biological Differences between the Two NDF/Heregulin Receptors, ErbB-3 and ErbB-4" J Biol. Chem. 271:7620-7629		
	C06	COOPER, 2000, <u>The Cell: A molecular approach</u> , "Section 13: Cell Signaling; Receptor Protein-Tyrosine Kinase," 2 nd edition. ASM Press, Washington DC, Pages 1-6, Accessed September 15, 2005 from http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=cooper .		
	C07	CURTI, 1993, "Physical barriers to drug delivery in tumors" Crit. Rev. in Oncology/Hematology 14:29-39		
	C08	DERMER, 1994, "Another Anniversary for the War on Cancer." Bio/technology 12:320		
	C09	DREBIN et al., 1988, "Monoclonal antibodies reactive with distinct domains of the <i>neu</i> oncogene-encoded p185 molecule exert synergistic anti-tumor effects <i>in vivo</i> ." Oncogene 2:273-277		
	C10	FENDLY et al., 1990, "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/ <i>neu</i> Gene Product." Cancer Res. 50:1550-1558		
	C11	FRESHNEY, 1983, Culture of Animal cells: A manual of Basic Technique. Alan R. Liss., Inc. New York		
	C12	GELLNER & BRENNER, 1999, "Analysis of 148 kb of genomic DNA around the wnt1 locus of Fugu rubripes." Genome Res 9(3):251-258		
	C13	GENBANK Accession No: AF056116, "Fugu rubripes serine/threonine kinase receptor type1, All-1 related protein (ALR), fugu hedgehog (fhh), Ikaros-like, wnt1, wnt10b, ARF3, erbB3, PAS1, and L41 ribosomal protein genes, complete cds; LRP1 gene, partial cds; and unknown genes," dated April 15, 1999		
	C14	GENBANK Accession No: M29366, "Human epidermal growth factor receptor (ERBB3) mRNA, complete cds," dated April 23, 1993		
	C15	GENBANK Accession No: U29339, "Rattus norvegicus ErbB3/Her3 precursor mRNA, complete cds," dated Dec. 5, 2001		
	C16	GURA, 1997, "Systems for identifying new drugs are often faulty." Science 278:1041-1042		
	C17	HAMID, 2004, "Emerging Treatments in Oncology: Focus on Tyrosine Kinase (erbB) Receptor Inhibitors." J Am. Pharm Assoc. 44:52-58		
	C18	HELLYER et al., 1995, "Cloning of the rat ErbB3 cDNA and characterization of the recombinant protein." Gene 165(2):279-284		
	C19	HOLBRO et al., 2003, "The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation." Proc. Natl. Acad. Sci. 100:8933-8938		
	C20	HUDSON & SOURIAU, 2003, "Engineered antibodies." Nat. Med. 9:129-134		
	C21	INTERNATIONAL SEARCH REPORT of Application No. PCT/AU00/00671, dated August 30, 2000		
	C22	INTERNATIONAL SEARCH REPORT of Application No: PCT/CN03/00217, dated Jun. 5, 2003		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11748-006-999	10/516,759
	APPLICANT	
	Mingdong Zhou	
	FILING DATE	ART UNIT
	March 3, 2006	1642

U.S. PATENT DOCUMENTS					
*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	C23	JAIN, 1994, "Barriers to drug delivery in solid tumors." Sci. Am. 271:58-65			
	C24	KASPRZYK et al., 1992, "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies." Cancer Res. 52:2771-2776			
	C25	KLAPPER et al., 1997, "A Subclass of Tumor-Inhibitory Monoclonal Antibodies to Erb-2/HER2 Blocks Crosstalk with Growth Factor Receptors." Oncogene 14:2099-2109			
	C26	KLAPPER et al., 1999, "The ErbB-2/HER2 Oncoprotein of Human Carcinomas May Function solely as a shared coreceptor for multiple Stroma-Derived Growth Factors." Proc. Natl. Acad. Sci 96:4995-5000			
	C27	KRAUS et al., 1989, "Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors." Proc. Natl. Acad. Sci. 86:9193-9197			
	C28	LAB VISION NeoMarkers data sheet (Ab105) "c-erbB-3/HER-3 Ab-5 (Clone H3.105.5; same as Ab105)" Accessed February 23, 2008 from http://www.labvision.com			
	C29	LEE et al., 2001, "A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4." Cancer Res 61:4467-4473			
	C30	LILLEHOJ et al., 1993, "Adjuvant activity of dimethyl dioctadecyl ammonium bromide, complete Freund's adjuvant and Corynebacterium parvum with respect to host immune response to coccidial antigens." Avian Dis 37(3):731-740			
	C31	MENDROLA et al., 2002, "The Single Transmembrane Domains of ErbB Receptors Self-associate in Cell Membranes." J. Biol. Chem. 27:4704-4712			
	C32	PARK et al., 1999, "Induction of the Tat-Binding Protein 1 Gene Accompanies the Disabling of Oncogenic ErbB receptor tyrosine kinases." Proc. Natl. Acad. Sci 96:6434-6438			
	C33	PINKAS-KRAMARSKI et al., 1998, "The Oncogenic ErbB-2/ErbB-3 Heterodimer is a Surrogate Receptor for Epidermal Growth Factor and Betacellulin." Oncogene 16:1249-1258			
	C34	PLOWMAN et al., 1990, "Molecular cloning and expression of an additional epidermal growth factor receptor-related gene." Proc. Natl. Acad. Sci 87:4905-4909			
	C35	RAM et al., 1996, "Mitogenic Activity of Neu Differentiation Factor//Heregulin Mimics that of Epidermal Growth Factor and Insulin-Like Growth Factor-I in Human Mammary epithelial cells." J. cell. Physiol 169:589-596			
	C36	RATIFF et al., 1992, "Role of the immune response in BCG for bladder cancer." Eur. Urol. 2 (Suppl):17-21			
	C37	SCHAEFER et al., 2006, "Potential use of humanized antibodies in the treatment of breast cancer." Expert Rev. Anticancer. Ther. 6:1065-1074			
	C38	SLIWKOWSKI et al., 1995, "Co-Expression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin." J. Biolog. Chem. 269(20):14661-14665			
	C39	STANCOVSKI et al., 1991, "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth." Proc. Natl. Acad. Sci. 88:8691-8695			
	C40	STERN & HERRMAN, 2005, "Overview of monoclonal antibodies in cancer therapy: present and promise." Crit. Rev in Oncology/Hematology 54:11-29			
	C41	SUPPLEMENTARY European Search Report for European Application No: EP 00 93 6539, mailed on April 29, 2005			
	C42	VIJAPURKAR et al., 1998, "Mutation of a Shc Binding Site tyrosine residue in ErbB3/Her3 Blocks Heregulin Dependent Activation of Mitogen-Activated Protein Kinase." J. Biol. Chem. 273(33):20996-21002			
	C43	YEON & PEGRAM, 2005, "Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer." Invest. New Drugs 23:391-409			

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	